期刊文献+

人乳头瘤病毒衣壳蛋白结构生物学研究进展 被引量:4

Advances in structural biology of human papillomavirus capsid proteins
下载PDF
导出
摘要 人乳头瘤病毒(human papillomavirus,HPV)的感染会导致人类多种疾病,尤其是女性宫颈癌。HPV衣壳是由主要衣壳蛋白L1和次要衣壳蛋白L2形成的T=7的正二十面体结构,L1蛋白具有较强的免疫原性且能在体外自组装形成与天然病毒结构相似的类病毒颗粒(virus like particle,VLP),是目前HPV疫苗的理想形式。此外,L1、L2蛋白在病毒的感染中发挥着重要作用。对HPV衣壳蛋白结构和功能的研究,有助于进一步阐明HPV的颗粒组装机制、致病机理及感染机制,为今后开展HPV相关疾病的研究提供指导方向。本文就HPV衣壳蛋白的结构、病毒颗粒组装及衣壳蛋白间相互作用研究进展进行综述。 Human papillomavirus (HPV) infection can induce several epithelial cancers, especially cervical cancer. HPV has a T = 7 icosahedral capsid which is composed of L1 major capsid protein and L2 minor capsid protein. L1 protein has strong immunogenicity and can self-assemble into virus like particles (VLPs) which are structurally and immunologically similar to the native virions and have been considered as the ideal form of the current vaccine. In addition, both L1 and L2 proteins play an important role in viral infection. Therefore, study of the structures and the functions of the capsid proteins will help to elucidate the mechanisms of particle assembly, virus infection and pathogenesis, and provide insights for the research of HPV related diseases in the future. This review focuses on the research progress in structure, assembly conditions and the interaction of HPV capsid proteins.
出处 《中国生化药物杂志》 CAS 2016年第5期20-23,27,共5页 Chinese Journal of Biochemical Pharmaceutics
关键词 人乳头瘤病毒 衣壳蛋白 结构生物学 human papillomavirus capsid protein structural biology
  • 相关文献

参考文献39

  • 1de Villiers E-M. Cross-marls in the classification of papillomavimses [ J ]. Virology, 2013, 445 ( 1 ) : 2-10.
  • 2Cubie HA. Diseases associated with human papillomavirus infection[ J]. Virology, 2013, 445(1) : 21-34.
  • 3Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Center ) [ R ]. Human Papillomavirus and Related Diseases in the World. 2015.
  • 4Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in China's Mainland [ J ]. Asian Pac J Cancer Prey, 2011, 12 (5) : 1149 - 1153.
  • 5Kushnir N,Streatfield S J, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development[J]. Vaccine, 2012, 31 ( 1 ) : 58- 83.
  • 6Schiller JT, Castellsagu6 X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines[ J ]. Vaccine, 2012 ( 30 ) :F123-F138.
  • 7Joura EA,Giuliano AR, Iver'n OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[ J]. New Engl J Med, 2015, 372(8): 711-723.
  • 8Richards KF, Bienkowska-Haba M, Dasgupta J, et al. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16 [ J ]. J Virol, 2013, 87 (21) : 11426-11437.
  • 9Buck CB,Day PM, Trus BL. The papiUomavirus major capsid protein L1[J]. Virology, 2013, 445(1): 169-174.
  • 10Karanam B, Jagu S, Huh WK, et al. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection[ J]. Immunol Cell Biol, 2009, 87(4): 287-299.

同被引文献23

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部